Active Cardiac Troponin I (cTnI)

Catalog#:PEH12375

概述（Summary）

别称（Alternative Names）	TNNI3; TNNC1; CMH7; C-TnI; Troponin I Type 3; Troponin I Type 3, Cardiac
纯度（Purity）	Greater than 97% as determined by reducing SDS-PAGE.
内毒素（Endotoxin level）	Please contact with the lab for this information
蛋白构建（Construction）	【Met1-Gly203】
Accession #	P19429
表达宿主（Host）	E.coli
种属（Species）	Homo sapiens (Human)
预测分子量（Predicted MW）	26.8 kDa
制剂（Form）	Lyophilized from a 0.2 μm filtered solution of 20mM Tris, 150mM NaCl, pH8.0, containing 1mM EDTA, 1mM DTT, 0.01% SKL, 5% Trehalose and Proclin300.
运输方式（Shipping）	The product is shipped with ice bag. Upon receipt, store it immediately at the temperature listed below.
稳定性&储存（Stability &Storage）	12 months at -20°C to -80°C in lyophilized state.6 months at -20°C to -80°C under sterile conditions after reconstitution.7-10 days at 2°C to 8°C under sterile conditions after reconstitution.Please minimize freeze-thaw cycles.
复溶（Reconstitution）	Reconstitute in 20mM Tris, 150mM NaCl (pH8.0) to a concentration of 0.1-1.0 mg/mL. Do not vortex.
背景介绍（References）	Troponin I is the inhibitory subunit of troponin, the thin filament regulatory complex which confers calcium-sensitivity to striated muscle actomyosin ATPase activity.

电泳图（SDS-PAGE image）



Greater than 97% as determined by reducing SDS-PAGE.

活性图（Bioactivity image）



Figure. The binding activity of TNNI3 with TNNT2. Troponin I Type 3, Cardiac (TNNI3) is a protein that in humans is encoded by the TNNI3 gene. It is a tissue-specific subtype of troponin I, which in turn is a part of the troponin complex. The TNNI3 gene encoding cardiac troponin I (cTnI) is located at 19q13.4 in the human chromosomal genome. Human cTnI is a 24kDa protein consisting of 210 amino acids with isoelectric point (pI) of 9.87. cTnI is exclusively expressed in adult cardiac muscle. Besides, Troponin T Type 2, Cardiac (TNNT2) has been identified as an interactor of TNNI3, thus a binding ELISA assay was conducted to detect the interaction of recombinant human TNNI3 and recombinant human TNNT2. Briefly, TNNI3 was diluted serially in PBS with 0.01% BSA (pH 7.4). Duplicate samples of 100µL were then transferred to TNNT2-coated microtiter wells and incubated for 2h at 37℃. Wells were washed with PBST and incubated for 1h with anti-TNNI3 pAb, then aspirated and washed 3 times. After incubation with HRP labelled secondary antibody, wells were aspirated and washed 3 times. With the addition of substrate solution, wells were incubated 15-25 minutes at 37℃. Finally, add 50µL stop solution to the wells and read at 450nm immediately. The binding activity of TNNI3 and TNNT2 was shown in Figure 1, and this effect was in a dose dependent manner.

注意事项（Note）

For Research Use Only , Not for Diagnostic Use.